ClinicalTrials.gg
CompletedNCT01369745SynergyUpdated May 15, 2014Results posted

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

A Phase 2 interventional study of Prednisolone and dipyridamole in Rheumatoid Arthritis, sponsored by Zalicus. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-15.

Sponsored by Zalicus · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Enrollment
216th of 771
294 · median 120
Started
2011
with 69 others
Phase 2
215 of 975
12 open now
Registered
401st of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 216th largest by enrollment of the 771 interventional ones that give a count, is one of 70 that started in 2011, is one of 215 in phase 2, and was the 401st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

Thus study will test an experimental drug called Z-102 (combination of prednisolone and dipyridamole) to treat patients with moderate to severe rheumatoid arthritis.

Read the detailed description

The primary objective of the study was to demonstrate the efficacy of Z102 (2.7 mg prednisolone/360 mg dipyridamole) versus placebo on the Disease Activity Score 28 using C reactive protein (DAS28-CRP) in subjects with rheumatoid arthritis at the study endpoint of 12 weeks

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Moderate to severe
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the ACR / EULAR criteria for classification of RA
  • Have moderate to severe RA, defined as involving a minimum (≥6 total swollen and ≥6 total tender) of the 28 joints assessed
  • Have screening CRP levels of at least 0.6 mg/dl and a DAS28-CRP score ≥4.5
  • Have been on a stable dose of conventional DMARD therapy for at least 90 days without dosage adjustment or modification and should be able to maintain the same dose of conventional DMARD therapy during study participation (with or without therapy

Exclusion criteria

Exclusion Criteria:

  • Treatment- patients are excluded
  • Has active cardiovascular disease, unless well controlled by appropriate treatment for a minimum of 3 months prior to screening
  • Is taking aspirin for reasons other than for cardiovascular prophylaxis or their total daily dose is greater than 325 mg
  • Is currently taking at a daily prednisone dose, or the equivalent, of >10 mg
  • Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering the study
  • The need to continue the use of one or multiple NSAID's at the same time, or the use of acetaminophen on a chronic basis
  • All opiate use is prohibited
  • Use of any other medications or herbs used for the treatment of pain is prohibited
  • Patients with a history of or currently active tuberculosis as per specific country guidelines are excluded
  • Has uncontrolled diabetes mellitus as defined by a serum glucose >126 mg/dl
  • Knowingly has infection or hepatitis
  • Has undergone administration of any drug within 30 days of study initiation
  • All biologic agents are excluded for 90 days prior to Screening and throughout the study.
  • Has undergone administration of rituximab or any B-cell depleting investigational drugs within 6 months of study initiation
  • Has had a history of alcohol or drug abuse within the past 2 years
  • Has a history of to glucocorticoids and/or dipyridamole
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
294 participants (actual)

Study arms

  • Active comparator
    Prednisolone

    Prednisolone 2.7 mg daily for 12 weeks

    Drug: Prednisolone

  • Active comparator
    dipyridamole

    Dipyridamole 360 mg daily for 12 weeks

    Drug: dipyridamole

  • Active comparator
    prednisone

    Prednisone 5 mg daily for 12 weeks

    Drug: Prednisone

  • Experimental
    Z102 (2.7/360)

    Prednisolone 2.7 mg plus dipyridamole 360 mg daily for 12 weeks

    Drug: Z102

  • Placebo comparator
    placebo

    Placebo daily for 12 weeks

    Other: placebo

Interventions

  • Prednisolone 2.7 mg daily

  • dipyridamole 360 mg daily

  • Prednisone 5 mg daily

  • DrugZ102

    Prednisolone 2.7 mg plus dipyridamole 360 mg daily

    Also known as: prednisolone, dipyridamole

  • Otherplacebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline in DAS28-CRP at 12 Weeks

    The primary efficacy endpoint was the mean change in Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12. The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤3.2 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.

    Time frame: baseline to week 12

Secondary outcomes

  1. Change From Baseline in DAS28-CRP Individual Components at 12 Weeks

    The mean change in the individual components of the Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12 which included individual assessment of Tender Joint Count (28-joint assessment), Swollen Joint Count (28-joint assessment), Patient Global Assessment of Disease Activity and absolute CRP level. In each case, higher scores indicate more disease activity. The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity.

    Time frame: Baseline to week 12

  2. Percentage of Subjects Achieving ACR20, ACR50 and ACR70 at 12 Weeks

    The American College of Rheumatology (ACR) 20 is a widely accepted composite index of improvement in RA proposed by the ACR (Fransen and van Riel 2009). ACR20 refers to a composite improvement of 20% in swollen joint count, tender joint count, and 3 or more of the following 5 measures:Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient Pain VAS, Patient's self-addressed disability (HAQ) (Arnet 1988 and Felson 1995), Acute-phase reactant (ESR or CRP) The ACR 50 and ACR 70 are similar tools, used to indicate 50% and 70% improvement, respectively.

    Time frame: Week 12

  3. Multidimensional Assessment of Fatigue (MAF) at Week 12

    The Multidimensional Assessment of Fatigue (MAF) scale contains 16 items and measures four dimensions of fatigue: severity (#1-2), distress (#3), degree of interference in activities of daily living (#4-14), and timing (#15-16). Fourteen items contain numerical rating scales (#1-14) and two items have multiple-choice responses (#15-16). Respondents are asked to reflect on fatigue patterns for the past week. To calculate the Global Fatigue Index (GFI): Convert item #15 to a 0-10 scale by multiplying each score by 2.5 and then sum items #1, 2, 3, average #4-14, and newly scored item #15. Scores range from 1 (no fatigue) to 50 (severe fatigue). Do not assign a score to items #4-14 if respondent indicated they "do not do any activity for reasons other than fatigue." If respondents select no fatigue on item #1, assign a zero to items #2-16. Item #16 is not included in the Global Fatigue Index.

    Time frame: week 12

  4. Time to Failure (Days)

    Patients will be monitored for addition of any DMARD or withdrawal due to flare. The time to failure is defined as the duration of study participation (in days) until a qualifying event or completion of study treatment, whichever comes first.

    Time frame: Baseline to 12 weeks

07

Results

Posted Apr 30, 2014
Limitations and caveats
The study did not progress past the first stage of adaptive randomization. The number of subjects allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg arms was insufficient to allow analysis of the secondary objectives.

Participant flow

Participant flow — Overall Study
MilestonePrednisoloneDipyridamolePrednisoneZ102Placebo
Started3241188483
Completed2528166465
Not completed71322018

Outcome measures

PrimaryChange From Baseline in DAS28-CRP at 12 Weeks

The primary efficacy endpoint was the mean change in Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12. The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤3.2 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.

Time frame:
baseline to week 12
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-CRP at 12 Weeks
units on a scalePrednisoloneDipyridamolePrednisoneZ102Placebo
Change From Baseline in DAS28-CRP at 12 Weeks-1.147 ± 0.235-0.813 ± 0.216-1.237 ± 0.296-0.907 ± 0.149-0.538 ± 0.153
SecondaryChange From Baseline in DAS28-CRP Individual Components at 12 Weeks

The mean change in the individual components of the Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12 which included individual assessment of Tender Joint Count (28-joint assessment), Swollen Joint Count (28-joint assessment), Patient Global Assessment of Disease Activity and absolute CRP level. In each case, higher scores indicate more disease activity. The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity.

Time frame:
Baseline to week 12

No measurements were reported for this outcome.

SecondaryPercentage of Subjects Achieving ACR20, ACR50 and ACR70 at 12 Weeks

The American College of Rheumatology (ACR) 20 is a widely accepted composite index of improvement in RA proposed by the ACR (Fransen and van Riel 2009). ACR20 refers to a composite improvement of 20% in swollen joint count, tender joint count, and 3 or more of the following 5 measures:Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient Pain VAS, Patient's self-addressed disability (HAQ) (Arnet 1988 and Felson 1995), Acute-phase reactant (ESR or CRP) The ACR 50 and ACR 70 are similar tools, used to indicate 50% and 70% improvement, respectively.

Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryMultidimensional Assessment of Fatigue (MAF) at Week 12

The Multidimensional Assessment of Fatigue (MAF) scale contains 16 items and measures four dimensions of fatigue: severity (#1-2), distress (#3), degree of interference in activities of daily living (#4-14), and timing (#15-16). Fourteen items contain numerical rating scales (#1-14) and two items have multiple-choice responses (#15-16). Respondents are asked to reflect on fatigue patterns for the past week. To calculate the Global Fatigue Index (GFI): Convert item #15 to a 0-10 scale by multiplying each score by 2.5 and then sum items #1, 2, 3, average #4-14, and newly scored item #15. Scores range from 1 (no fatigue) to 50 (severe fatigue). Do not assign a score to items #4-14 if respondent indicated they "do not do any activity for reasons other than fatigue." If respondents select no fatigue on item #1, assign a zero to items #2-16. Item #16 is not included in the Global Fatigue Index.

Time frame:
week 12

No measurements were reported for this outcome.

SecondaryTime to Failure (Days)

Patients will be monitored for addition of any DMARD or withdrawal due to flare. The time to failure is defined as the duration of study participation (in days) until a qualifying event or completion of study treatment, whichever comes first.

Time frame:
Baseline to 12 weeks

No measurements were reported for this outcome.

Adverse events

Collected over Adverse event data were collected from the time of consent through the end of study visit at 12 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prednisolone—1/32 (3.1%)6/32 (18.8%)
Dipyridamole—2/41 (4.9%)30/41 (73.2%)
Prednisone—0/18 (0%)5/18 (27.8%)
Z102—5/84 (6%)38/84 (45.2%)
Placebo—4/83 (4.8%)33/83 (39.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPrednisoloneDipyridamolePrednisoneZ102Placebo
Oedema PeripheralGeneral disorders1/320/410/180/840/83
Angina PectorisCardiac disorders0/321/410/180/840/83
Calculus UretericRenal and urinary disorders0/321/410/180/840/83
SciaticaNervous system disorders0/320/410/182/841/83
Haemolytic AnaemiaBlood and lymphatic system disorders0/320/410/180/841/83
Ureteric ObstructionRenal and urinary disorders0/320/410/180/841/83
Deep Vein ThrombosisVascular disorders0/320/410/180/841/83
Hip FractureInjury, poisoning and procedural complications0/320/410/181/840/83
Humerus FractureInjury, poisoning and procedural complications0/320/410/181/840/83
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders0/320/410/181/840/83
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPrednisoloneDipyridamolePrednisoneZ102Placebo
HeadacheNervous system disorders1/3211/410/1813/844/83
ArthralgiaMusculoskeletal and connective tissue disorders1/323/411/185/848/83
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders0/323/411/185/844/83
Back PainMusculoskeletal and connective tissue disorders1/323/410/181/841/83
Abdominal Upper PainGastrointestinal disorders1/323/410/181/841/83
NauseaGastrointestinal disorders0/322/411/183/841/83
DiarrhoeaGastrointestinal disorders0/321/411/182/841/83
NasopharyngitisInfections and infestations1/321/411/181/844/83
VertigoEar and labyrinth disorders0/322/410/181/840/83
Oedema PeripheralGeneral disorders1/320/410/180/842/83

Baseline characteristics

population randomized to double blind phase of study and recieved at least one dose of study drug

Age, Continuous
Age, Continuous(years)PrednisoloneDipyridamolePrednisoneZ102PlaceboTotal
Mean55.2 ± 12.6955.9 ± 9.3555.5 ± 9.8254.5 ± 11.5353.7 ± 12.4454.6 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)PrednisoloneDipyridamolePrednisoneZ102PlaceboTotal
Female2636177275226
Male65112832
08

Study locations

1 site
  • Zalicus Investigational Site
    Toledo, Ohio 43606, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Aug 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2011
First posted
Jun 9, 2011
Start
Jun 2011
Primary completionActual
Aug 2012
CompletionActual
Sep 2012
Results first posted
Apr 30, 2014
Last update
May 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01369745
Lead sponsor
Zalicus
Responsible party
Sponsor
First posted
Jun 9, 2011
Start date
Jun 2011
Primary completion
Aug 2012
Completion
Sep 2012
Results posted
Apr 30, 2014
Last update
May 15, 2014

Study contacts

Margaret Lee, PhD
study director · Zalicus, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisolone

Start the discussion